NEW CLINICAL STUDY RECRUITING MALES WITH CREATINE TRANSPORTER DEFICIENCY (CTD-SLC6A8)

Lumos Pharma is sponsoring a multi-year observational clinical study of males with Creatine Transporter Deficiency (CTD) that is currently recruiting individuals.

ClinicalTrials.gov Listing:  [https://clinicaltrials.gov/show/NCT02931682](https://clinicaltrials.gov/show/NCT02931682)

The Vigilan CTD observational study is a multiple site study that intends to enroll 50 males with CTD.

This study is designed to determine an appropriate clinical assessment battery for males with CTD, and to evaluate MRS along with other potential biomarkers. It is designed to explore developmental domains of interest and to examine the feasibility and utility of various neuropsychological assessments to measure domains of interest, and to identify possible endpoints for interventional studies. Study will also explore genotype-phenotype correlations.

Initial study locations include CHOP, NIH, Duke University and Rush University with more sites scheduled to open in Massachusetts, California, Ohio, Utah, Texas and Canada.

Please contact Aleksandra Bruchey, PhD at patients@lumos-pharma.com for more information.